Country And Site Strategy

The following discussion illustrates a project that is well suited to the capabilities of an independent consultant in the Umbrex Biotechnology Practice. This is an illustrative example. Umbrex consultants adapt their methodology, timeline, and deliverables to the specific needs of each client.

1) Client Situation

The client operated within the therapeutics-focused biotech ecosystem and required support with Country And Site Strategy in the context of Biotechnology. Teams across Emerging Therapeutic Biotech (Preclinical), Clinical-Stage Biotech (Phase I–III), Commercial Biotech (Post-Approval), Platform Biotech (Therapeutic Discovery), and Biotech Investors & Incubators sought a data-driven, repeatable approach to select countries and investigators, set allocations, and build contingency plans using epidemiology, investigator performance, and startup cycle-time data to achieve predictable enrollment. The diagnostic surfaced concrete pain points across indications and geographies:

• Country selection driven by anecdote, not incidence/prevalence and feasibility. Historical footprints and relationships governed site lists; true disease burden by region and catchment was not analyzed; healthcare coverage and access pathways were not incorporated, leading to low patient availability in selected regions.
• Investigator performance data underutilized. Prior site productivity (activation speed, enrollment/site/month, screen fail rate, retention, query and deviation rates) was not systematically tracked; sites were re-nominated despite subpar performance; new high-potential centers were missed.
• Start-up timelines unpredictable. Contracting, budget approval, and EC/IRB timelines varied widely by country and site; import licenses, central lab kit readiness, and data privacy reviews created unplanned delays; submissions were sequenced serially instead of in parallel.
• Competing trial intensity and referral networks not accounted for. Country/city-level congestion (competing trials, eligibility overlaps) was not analyzed; inter-site referral pathways and community partnerships were not established; central recruitment vendors were engaged late without data-driven targeting.
• Diversity and access goals not met. Site mix did not reflect demographic distribution of the target population; language coverage, transportation constraints, and payer realities reduced reach to underrepresented groups.
• Budget creep without throughput gains. High monitor days and travel costs persisted in low-yield geographies; duplicative vendors added overhead; SOWs lacked throughput and data-quality KPIs tied to capacity and escalation.
• Insufficient contingency and trigger planning. Country and site additions were reactive; expansion triggers were undefined; exposure to single-country risk (holidays, regulatory changes, geopolitical events) caused enrollment stalls.
• KPI underperformance signals. Start-up cycle time exceeded benchmarks by 30–50%; screen failure rate >40% at several anchor sites; enrollment <0.3 patients/site/month; retention <85% at LSLV; amendment-induced resubmission cycles increased calendar risk.

Executives requested a robust country and site strategy grounded in epidemiology, investigator performance, and start-up cycle-time analytics—with clear allocations, diversity overlays, and contingency triggers—to create predictable, budget-compliant enrollment timelines across the portfolio.

2) Project Objective

The primary objective focused on using epidemiology, investigator performance, and start-up cycle-time data to select countries and sites, set initial and contingency allocations, and orchestrate start-up to achieve predictable enrollment and data quality within budget and diversity targets.

Secondary objectives included:

• Building a geospatial model that integrates incidence/prevalence, eligibility computability, treatment patterns, and competing trial density to prioritize countries and metropolitan catchments.
• Developing standardized site scorecards with historical activation/enrollment productivity, data quality, retention, query/deviation rates, and monitoring findings to guide selection and allocations.
• Designing a country start-up playbook with cycle-time benchmarks (CTA, budget, EC/IRB, import) and parallelization tactics to compress FPFV timelines.
• Embedding diversity, equity, and inclusion (DEI) coverage into country/site selection and patient support plans to achieve representative enrollment.
• Instituting a probabilistic enrollment forecast with triggers for site expansion, country add/drop, and central recruitment activation; linking to budget and vendor capacity.
• Standing up vendor governance (CROs, SMOs, recruitment, central labs, imaging) with KPIs tied to start-up speed, enrollment velocity, and data quality; establishing QBRs and escalation ladders.
• Codifying a repeatable process, templates, and dashboards that scale across indications and phases.

3) Methodology and Approach

Workstream 1: Epidemiology and Geospatial Prioritization

We quantified where eligible patients were and which catchments were realistically accessible to high-performing sites.

• Activities we conducted:
  • Integrated epidemiology sources (literature-based incidence/prevalence, registries, payer claims, EHR-derived cohorts), filtered by age/sex and relevant comorbidities.
  • Applied computable eligibility where feasible to EHR/claims cohorts to estimate the truly eligible pool; overlaid treatment patterns (lines of therapy, referral pathways) and access constraints (reimbursement/coverage).
  • Mapped competing trial intensity (call for patients, overlapping criteria, sponsor reputation effects) at country and metro levels; scored congestion risk.
• Tools/frameworks:
  • Geospatial heat maps with eligibility-adjusted density, catchment radii, and travel-time isochrones; congestion index; site proximity clustering to minimize cannibalization.
• Stakeholders:
  • Clinical development, feasibility, medical affairs, HEOR/market access, regional regulatory.

Workstream 2: Investigator Performance Analytics and Site Scorecards

We created fact-based site selection and allocations using productivity and quality history.

• Activities we conducted:
  • Consolidated CTMS, EDC, monitoring, and QA data for historical studies: activation cycle time, enrollment/site/month, screen-to-randomization conversion, retention, protocol deviation and query rates, data lock timeliness, audit/inspection findings, SDV/RBM metrics.
  • Developed site scorecards with peer benchmarks by indication and phase; calibrated for sponsor/CRO effects; flagged high-variance performance and staff turnover risk.
  • Clustered sites into anchor, accelerator, and exploratory tiers; set initial allocation per tier; defined eligibility for contingency activation.
• Tools/frameworks:
  • Site productivity scorecards; quality composite indices; Bayesian shrinkage to stabilize sparse site data; site tiering logic.
• Stakeholders:
  • Clinical operations/start-up, CRO feasibility and country leads, QA/GCP, data management, medical monitors.

Workstream 3: Start-up Cycle-Time Modeling and Country Playbooks

We reduced time-to-FPFV by codifying parallelization and removing structural bottlenecks.

• Activities we conducted:
  • Modeled country and site start-up steps and lead times (CTA, contract/budget, EC/IRB, import/export licenses, central lab kit readiness, translations, data privacy assessments).
  • Benchmarking and gap closure: applied median and P75 benchmarks by region; redesigned process for parallel submissions; created template CTAs and budget shells; pre-negotiated country-specific clauses with central and local ECs where possible.
  • Built country playbooks with regulatory calendars, holiday impacts, vendor readiness (courier routes, temperature-controlled logistics), and sponsor/CRO responsibilities.
• Tools/frameworks:
  • Start-up control tower, critical path maps, country readiness score, and contract clause libraries.
• Stakeholders:
  • Start-up leads, legal/contracts, regional regulatory, supply chain/logistics, central lab/imaging, CRO start-up managers.

Workstream 4: Allocation Strategy and Contingency Triggers

We set initial allocations and pre-defined when and where to expand or pivot.

• Activities we conducted:
  • Allocated target randomizations to countries and site tiers based on eligible pool size, start-up speed, historic productivity, and congestion risk; built monthly enrollment ramp curves by site.
  • Defined triggers (e.g., two consecutive periods below P25 of forecast, start-up slippage beyond threshold, screen failure spike) with pre-approved add/drop lists; secured regulatory feasibility for fast-add geographies.
  • Calibrated central recruitment/referral networks and patient support programs (transport, lodging) with activation thresholds.
• Tools/frameworks:
  • Monte Carlo enrollment model, trigger/action matrix, heat maps of reserve sites, and “ready-to-activate” dossier checklist.
• Stakeholders:
  • Program leadership, clinical operations, finance/FP&A, CRO PMO, patient recruitment partners.

Workstream 5: Diversity, Equity, and Inclusion (DEI) Coverage

We built representative enrollment by design rather than aspiration.

• Activities we conducted:
  • Mapped disease burden by race/ethnicity/sex/age; identified underrepresented groups by geography; overlaid language access and socioeconomic indicators (transportation deserts, median income).
  • Adjusted country/site mix and allocations; added community-based and Federally Qualified Health Centers (where relevant); built community partnerships and satellite referral clinics.
  • Implemented patient support (transport vouchers, childcare stipends, multilingual materials, extended clinic hours) and tracked DEI metrics.
• Tools/frameworks:
  • DEI coverage index, site DEI readiness assessment, and patient support ROI model.
• Stakeholders:
  • Clinical leadership, patient advocacy, community engagement, sites, recruitment vendors, medical affairs.

Workstream 6: Central Recruitment, Referrals, and DCT Overlays

We expanded reach and reduced burden with targeted recruitment and hybrid visits.

• Activities we conducted:
  • Configured central recruitment channels (digital, call centers) with geo-targeting based on the eligible density model; established referral workflows between anchor centers and satellite clinics.
  • Integrated decentralized clinical trial (DCT) components (eConsent, ePRO/eCOA, telemedicine, home health) to widen catchment and reduce required travel, aligned with local regulations.
  • Validated patient journey touchpoints and conversion analytics (awareness → prescreen → screening → randomization → retention).
• Tools/frameworks:
  • Recruitment targeting engine, referral network SOPs, DCT operational playbook, and funnel analytics dashboards.
• Stakeholders:
  • Recruitment vendors, clinical operations, IT/eClinical, sites, legal/privacy.

Workstream 7: Vendor Governance and QBR Discipline

We aligned vendor incentives with throughput and quality.

• Activities we conducted:
  • Redlined SOWs with performance KPIs (start-up cycle time, enrollment velocity, screen failure conversion, data query rate, retention), service credits/bonuses, and change-order controls.
  • Instituted QBRs with CROs/SMOs/central lab/imaging/recruitment vendors; built capacity calendars; documented “Plan B” vendor options for priority markets.
  • Set escalation ladders and issue-resolution SLAs; integrated vendor performance into the control tower dashboard.
• Tools/frameworks:
  • Vendor KPI scorecards, QBR templates, capacity heatmaps, and service credit/penalty matrices.
• Stakeholders:
  • Procurement, clinical operations, CRO/vendor PMO, QA/GCP, finance.

Workstream 8: Data Architecture, Forecasting, and Control Tower

We enabled real-time monitoring of start-up and enrollment against plan with early warning signals.

• Activities we conducted:
  • Integrated CTMS, EDC, IxRS/IRT, central lab, and recruitment funnel data into dashboards; automated KPI refresh; defined data lineage and quality checks.
  • Ran rolling Monte Carlo forecasts; flagged variance-to-plan and benefits-at-risk; surfaced triggers for expansion or course correction.
• Tools/frameworks:
  • Country/site control tower dashboards, KPI dictionary (with lineage), and forecasting engine.
• Stakeholders:
  • Program leadership, clinical operations, data management/biostats, CRO PMO.

Workstream 9: Budget, Scenario Economics, and Trade-offs

We linked allocation choices to cost and cycle-time outcomes.

• Activities we conducted:
  • Built activity-based costing by country/site tier; compared scenarios (fewer high-throughput geographies vs. broad footprint; more DCT vs. onsite burden; central recruitment depth); quantified cost per randomization.
  • Aligned finance with trigger-based budget releases for expansion; established variance controls and contingency reserves tied to risks.
• Tools/frameworks:
  • Scenario P&L, cost-per-patient model, and budget control playbook.
• Stakeholders:
  • Finance/FP&A, procurement, program leadership, clinical operations.

Workstream 10: Change Management, Training, and Inspection Readiness

We ensured adoption and readiness for audits and HA queries.

• Activities we conducted:
  • Trained study teams on country playbooks, site scorecards, start-up templates, and control tower use; established governance with decision rights and escalation thresholds.
  • Prepared inspection storyboards (country/site selection rationale, DEI overlays, start-up cycle improvements, vendor KPIs, amendment prevention); documented data lineage, source systems, and decision logs.
• Tools/frameworks:
  • Training kits, SOP updates, inspection readiness binders, and decision logs.
• Stakeholders:
  • Clinical operations, QA/GCP, CRO partners, program leadership.

4) Data Request

We requested the datasets and artifacts required to design the country and site strategy and enable forecasting and governance. Typical horizons were 12–36 months historical and current-year forward plans.

• Epidemiology and RWD:
  • Incidence/prevalence by country/region; de-identified EHR/claims with computable eligibility variables; treatment patterns (lines of therapy); referral pathways; payer coverage/access constraints.
• Competing trials and feasibility:
  • Country and metro-level trial density (indication, phase, eligibility overlap); investigator feasibility responses; site capabilities (equipment, staff, specialties); language and hours of operation.
• Site performance and quality:
  • CTMS extracts for activation timelines, enrollment velocity, screen fail reasons, retention; EDC metrics (query/deviation rates, data lock timeliness); monitoring findings; audit/inspection outcomes.
• Start-up and regulatory:
  • Country start-up timelines (CTA, contract/budget, EC/IRB), import/export license requirements, data privacy assessments, translation timelines, holidays/regulatory calendars.
• Vendor and capacity:
  • CRO/SMO capacity by country, central lab/imaging courier networks, recruitment vendor footprint, logistics (temperature-controlled lanes), kit readiness lead times.
• DEI and patient support:
  • Demographics by geography, language coverage, transportation access, community partnerships; prior DEI performance; patient support cost norms.
• Systems and governance:
  • CTMS/EDC/IRT integrations; data lineage documents; KPI definitions and refresh cadence; current dashboards; governance calendars and escalation rules.
• Budget and SOWs:
  • Country/site budgets, vendor SOWs and SLAs, change-order history, service credit structures, central recruitment costing models.

Common data pitfalls included incomplete or non-computable eligibility in EHR/claims, stale feasibility surveys, missing or inconsistent site performance metrics, variable startup timelines without root-cause coding, competing-trial data that missed local nuances, fragmented vendor capacity views, and dashboards without data lineage. We established a data dictionary, unified site scorecards, and a controlled repository before modeling and decision sessions.

5) Questions for Client

• What enrollment timeline and FPI/LSLV milestones are non-negotiable, and what buffers are acceptable at country and site levels?
• Which endpoints and eligibility criteria drive the heaviest screen failure; where is the team open to pragmatic relaxations without compromising safety?
• What is the minimum viable geographic footprint (countries and anchor metros) to de-risk timelines; how much single-country exposure is tolerable?
• Which historical sites must be protected, and which can be replaced if performance and feasibility data indicate risk?
• What DEI objectives are set for this program; what patient support measures (transport, stipends, hours/language) can we fund and operationalize?
• What start-up cycle-time targets (CTA, contract, EC/IRB) and parallelization tactics will you authorize; which country-specific constraints require senior escalation?
• Which vendors are locked vs. flexible; what KPIs and service credits will govern their performance; what backup options are acceptable?
• What triggers should activate country/site expansion or contraction; who approves activation of reserve sites and central recruitment?
• How should we balance central recruitment vs. site-driven outreach; what privacy and branding constraints apply?
• What budget guardrails and cost-per-randomization targets are in force; what trade-offs (DCT, site mix, ancillary support) are acceptable?
• How will governance operate (cadence, decision rights, escalation thresholds) to prevent drift and late, reactive changes?

6) Interview Guide for Subject Matter Experts

Clinical Operations / Start-up Lead

• Where do start-up bottlenecks most often occur (CTA, contract, EC/IRB, import); what regional templates and parallelization have worked?
• Which countries and sites consistently outperform or underperform; what are the root causes?
• How do you measure site productivity and quality today; where are metric gaps?

Feasibility / Country Leads (Sponsor/CRO)

• How does current feasibility incorporate epidemiology and competing-trial intensity; where do local nuances alter the global picture?
• What MOH/regulatory or country privacy constraints impact DCT, central recruitment, or data flows?
• Which reserve sites and countries could be activated within 60–90 days?

Biostatistics / Data Science

• How do eligibility and endpoint choices shape the size of the eligible population; what RWD sources are available for computability?
• What enrollment forecasting methods are in place; how should Monte Carlo assumptions be calibrated?
• What sensitivity analyses will bound enrollment risk under alternative allocations?

Medical Affairs / Investigators

• Which centers manage the most patients who match the protocol phenotype; how do referral patterns work for this disease?
• What barriers to enrollment (visit burden, reimbursement) are most material; what mitigations are realistic?

Patient Advocacy / Community Engagement

• Which geographies and site types best reach underrepresented groups; what support services move the needle?
• How should outreach and education be tailored to local communities and languages?

Procurement / Vendor Management

• Which vendor contracts lack throughput KPIs or service credits; where do change orders proliferate?
• What alternative vendors are pre-qualified for rapid deployment if performance slips?

Central Lab / Imaging / Logistics

• Which routes and customs processes delay kit movement; where do local lab partnerships accelerate TAT without quality risk?
• What are rejection root causes; how should SoA/timepoint adjustments mitigate them?

QA/GCP and Data Management

• Which sites and countries show recurring quality issues (deviations, queries, data lag); what oversight adjustments reduce risk?
• How will RBM and centralized monitoring support quality while accelerating throughput?

7) Timeline

We executed a 12–14 week plan tailored to Country And Site Strategy within Clinical Development & Operations.

• Weeks 1–2: Diagnostic and Data Enablement
  • Compiled epidemiology, RWD, site performance, and start-up datasets; validated data lineage; baselined enrollment KPIs; confirmed governance cadence and decision rights.
  • Decision Gate A: Approved data sources, modeling assumptions, and diagnostic findings (eligibility-adjusted geography, performance outliers, start-up bottlenecks).
• Weeks 3–4: Geospatial Prioritization and Site Scorecards
  • Built eligibility-adjusted heat maps and competing-trial overlays; developed site scorecards; proposed country and anchor metro shortlists; classified sites into tiers.
  • Decision Gate B: Ratified country shortlist and site tiering; authorized deeper feasibility checks and vendor capacity validation.
• Weeks 5–6: Start-up Playbooks and Allocation Scenarios
  • Authored country playbooks (regulatory calendars, parallelization plans); modeled initial allocations and monthly ramp curves; calibrated DEI overlays; prepared contingency add/drop lists.
  • Decision Gate C: Approved initial allocations and DEI coverage; set triggers and reserve activation plan; aligned start-up targets and templates.
• Weeks 7–8: Forecasting, Control Tower, and Vendor KPIs
  • Implemented Monte Carlo forecast and dashboards; integrated CTMS/IRT/EDC data feeds; redlined vendor SOWs with throughput and quality KPIs; set QBR cadence and escalation ladders.
  • Decision Gate D: Endorsed control tower and vendor governance; confirmed budget ranges and contingency reserves.
• Weeks 9–10: Country Activation and DEI Execution
  • Launched start-up control tower; initiated central recruitment/referral networks; executed community outreach; deployed patient support services; confirmed logistics readiness (kits, couriers, import).
  • Decision Gate E: Verified FPFV forecast confidence; validated diversity coverage; locked remaining reserve site documentation.
• Weeks 11–12: Handoff and Ongoing Governance
  • Finalized country/site strategy dossier; transferred tools (scorecards, dashboards, playbooks) to the operational team; established weekly/biweekly reviews; codified amendment watch and expansion triggers.
  • Decision Gate F: Authorized launch of planned sites and countries; set cadence for quarterly portfolio refresh and KPI reviews.
• Weeks 13–14 (optional): Stress Tests and Audit Readiness
  • Executed stress tests on enrollment model (holiday periods, vendor shortfalls); completed inspection storyboards and documentation of selection rationale; tuned trigger thresholds and contingency budgets.

Critical path items included computable eligibility for geographic estimates, access to reliable competing-trial and site performance data, country regulatory parallelization feasibility, vendor capacity in priority markets, and alignment on diversity targets and patient support funding.

8) Deliverables

• Country and Site Strategy Dossier
  • Epidemiology- and eligibility-adjusted country/metro priorities; site tiering and allocation logic; DEI overlay; start-up playbooks; decision logs and governance.
• Geospatial Heat Maps and Eligibility Model
  • Incidence/prevalence and eligible patient density; travel-time isochrones; competing-trial intensity; catchment clustering and cannibalization analysis.
• Investigator Performance Scorecards
  • Activation speed, enrollment/site/month, screen failure, retention, query/deviation rates, data lag, audit/inspection history; tiering and recommended allocations.
• Start-up Control Tower and Country Playbooks
  • Regulatory calendars, parallelization tactics, contract/budget templates, EC/IRB trackers, import/logistics readiness; escalation rules and decision rights.
• Allocation Plan and Contingency Triggers
  • Country/site monthly ramp curves; trigger/action matrix; reserve site/country dossiers; central recruitment and referral activation plans.
• Diversity and Patient Support Plan
  • DEI coverage metrics, targeted sites/communities, patient support services (transport, lodging, childcare, language), and outreach playbook.
• Enrollment Forecast and KPI Dashboards
  • Monte Carlo projections, variance-to-plan, early warning thresholds; integrated CTMS/IRT/EDC dashboards; KPI dictionary and data lineage.
• Vendor Governance Toolkit
  • Redlined SOWs with KPIs, service credits/bonuses; QBR scorecards; capacity calendars; escalation ladders; change-order governance.
• Scenario Economics and Budget Model
  • Cost-per-randomization by scenario (footprint, DCT intensity, recruitment mix); contingency reserves and trigger-based releases; finance reporting pack.
• Inspection Readiness Storyboards
  • Country/site selection rationale, DEI design, start-up improvements, vendor performance management, and decision logs; evidence of data lineage and governance.

9) Industry Insights

• Epidemiology must be eligibility-adjusted
  • Raw incidence/prevalence overstates practical patient availability; computable eligibility applied to EHR/claims yields realistic estimates and prevents over-allocating to low-yield geographies.
• Past performance predicts future throughput
  • Site productivity and quality history—activation speed, enrollment velocity, deviations/queries—correlates with future performance; a tiered portfolio outperforms uniform allocation.
• Parallelization and templates compress start-up
  • Country playbooks with parallel submissions, templated contracts, and pre-negotiated clauses reduce time-to-FPFV; start-up control towers and escalation rules sustain speed.
• Competing-trial intensity matters at metro level
  • City-level congestion and overlapping eligibility drive cannibalization; allocation should consider trial density and referral networks, not just national totals.
• Diversity by design, not by afterthought
  • DEI goals are achievable when geographies, site types, language access, and patient support services are planned; regulators increasingly expect documented strategies and metrics.
• Hybrid/DCT unlocks catchment and retention
  • Telemedicine, home health, and ePRO/eCOA reduce travel and increase retention—especially in dispersed geographies—when SOPs, training, and data flows are robust and compliant.
• Contingency triggers stabilize timelines
  • Predefined expansion thresholds, reserve sites, and budgeted central campaigns turn variance into manageable course corrections rather than crises.
• Vendor accountability equals predictability
  • CRO and partner KPIs tied to start-up and enrollment throughput, with service credits/bonuses and QBRs, improve performance; capacity planning around peaks reduces slippage.
• What “good” looks like
  • A country/site plan anchored in eligibility-adjusted epidemiology and investigator performance; start-up playbooks and control towers; DEI coverage and patient support; probabilistic forecasts with triggers; vendor governance; and dashboards with lineage that keep enrollment predictable.
• Near-term watch points
  • Regulatory and privacy shifts affecting DCT and recruitment; geopolitical risks and customs bottlenecks; sudden spikes in competing-trial density; holiday and vacation season impacts; public payer policy changes. Quarterly portfolio refreshes maintain resilience.

Implications for clients we served included enabling Emerging Therapeutic Biotech to launch first studies with a right-sized, de-risked footprint; supporting Clinical-Stage Biotech to stabilize PoC/pivotal timelines with allocations and triggers; equipping Commercial Biotech to execute post-approval and RWE studies efficiently across markets; guiding Platform Biotech to standardize country/site playbooks across partnered programs; and providing Biotech Investors & Incubators with comparable, data-driven views of enrollment predictability and budget risk across portfolios.